<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00218348</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-16305-1</org_study_id>
    <secondary_id>R01DA016305</secondary_id>
    <secondary_id>R01-16305-1</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00218348</nct_id>
  </id_info>
  <brief_title>Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo</brief_title>
  <official_title>Pharmacotherapy for Cocaine Dependence - 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <brief_summary>
    <textblock>
      Dextro-amphetamine sulfate is a central nervous system stimulant that increases the release&#xD;
      of the neurotransmitter dopamine in the brain. The purpose of this study is to further&#xD;
      examine dose ranges of dextro-amphetamine sulfate as a treatment for cocaine dependence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, double-blind dose study will compare the effectiveness of three active&#xD;
      medication doses of dextro-amphetamine sulfate to placebo in the treatment of cocaine&#xD;
      dependence. Participants will be randomly assigned to one of the four following dosages of&#xD;
      dextro-amphetamine sulfate: 0 mg, 40 mg, 60 mg, or 80 mg. Participants will undergo a 2-week&#xD;
      stabilization period followed by a 25-week study period. The study period will include&#xD;
      administration of the stable medication dose for 21 weeks, followed by 1 week of dose&#xD;
      reduction, and then 3 weeks without medication. All participants will receive weekly&#xD;
      cognitive behavioral therapy and electrocardiograms. Participants will be given the option to&#xD;
      participate in a voluntary plasma blood draw during Weeks 4, 8, and 20 and will be scheduled&#xD;
      for follow-up assessments at Months 1 and 3 post-treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Substance use and retention</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness measures, including psycho-social variables, side effects, and self-reported measures</measure>
  </secondary_outcome>
  <enrollment type="Actual">186</enrollment>
  <condition>Cocaine-Related Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextro-Amphetamine Sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DSM-IV diagnosis of cocaine dependence, as determined by the Structured Clinical&#xD;
             Interview for DSM-IV&#xD;
&#xD;
          -  Agreement to use an adequate method of contraception for the duration of the study&#xD;
&#xD;
          -  Electrocardiogram confirmation by a cardiologist&#xD;
&#xD;
          -  Cocaine-positive urine test prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  High blood pressure&#xD;
&#xD;
          -  Significant heart disease&#xD;
&#xD;
          -  Clinically significant cardiovascular abnormality&#xD;
&#xD;
          -  Angina&#xD;
&#xD;
          -  Kidney, liver, or gastrointestinal disorder&#xD;
&#xD;
          -  Current Axis I disorder not related to drug use&#xD;
&#xD;
          -  Current dependence on any drug other than nicotine&#xD;
&#xD;
          -  Attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD)&#xD;
&#xD;
          -  On probation or parole for reasons other than those related to drug abuse charges&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Sought treatment for drug dependence within 3 months prior to study entry&#xD;
&#xD;
          -  Currently taking prescribed medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joy M Schmitz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>December 16, 2017</last_update_submitted>
  <last_update_submitted_qc>December 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Joy Schmitz</investigator_full_name>
    <investigator_title>Professor - Psy, Behavioral Science</investigator_title>
  </responsible_party>
  <keyword>Cocaine Abuse</keyword>
  <keyword>Dextro-Amphetamine Sulfate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

